Fusion - FPX-01-01

Site Image

Study Overview

A first-in-man Phase 1, non-randomized, multi-centre, open-label clinical trial designed to investigate the safety, tolerability, pharmacokinetics of [111In]-FPI-1547 Injection and [225Ac]-FPI-1434 Injection and to establish the maximum tolerated dose of a single [225Ac]-FPI-1434 Injection in patients with solid tumours with demonstrated tumour uptake of [111In]-FPI-1547. Includes a sub-study of FPI-1175 to measure its effect on the diagnostic capabilities of [111In]-FPI-1547

The research team will work closely with colleagues in the Phase I oncology group at Penn Medicine treating solid tumors. Most subjects will be getting treatment in the University of Pennsylvania Health System. Screening will be carried out by the Phase I and nuclear medicine groups and nuclear medicine study team as necessary.

Study Description

Participants will complete the following research procedures:
• Blood tests, urine tests, physical examination, ECGs, a biopsy and scans of your cancer (if you have not recently had either)
• An injection of the imaging study drug [111In] -FPI-1547 followed by four imaging scans over the course of one week
• An injection of the treatment study drug [225Ac]-FPI-1434
• Follow-up visits (in person or over the phone) which include a review of medications, how you are feeling

  • Study Identifier: 842694

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Sign-up

Participate in medical studies to develop new diagnostic and clinical treatments and improve current standards of care.

Sign Up Now!

If you need assistance finding a non-cancer study or if you have any questions, please email psom-ocr@pobox.upenn.edu